Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1473 - PD-L1 expression in primary tumours and paired lymph node metastases in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma: relationship with MSI status and prognosis 

Date

09 Sep 2017

Session

Poster display session

Presenters

Maria Svensson

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

M. Svensson1, D. Borg1, C. Hedner1, J. Eberhard1, B. Nodin1, K. Leandersson2, K. Jirström3

Author affiliations

  • 1 Department Of Clinical Sciences Lund, Oncology And Pathology, Sweden, Lund University, 22185 - Lund/SE
  • 2 Cancer Immunology, Department Of Translational Medicine, Lund University, Malmö, Sweden, Lund University, 22185 - Lund/SE
  • 3 Department Of Clinical Sciences Lund, Oncology And Pathology, Lund University, Lund, Sweden, Lund University, 22185 - Lund/SE
More

Resources

Abstract 1473

Background

Although neoadjuvant and/or adjuvant treatment enhances survival in patients with resectable esophageal and gastric (EG) cancer, the prognosis remains poor and there is a great need to identify novel treatment strategies and suitable biomarkers. The efficacy of immune-modulating therapies in EG cancer remains to be confirmed. Expression of programmed death ligand 1 (PD-L1) is, together with microsatellite instability (MSI) status, a putative biomarker of response to such therapies, but their prognostic value in EG cancer remains unclear. Therefore, the aim of this study was to examine the expression of PD-L1 in tumour cells (TC) and tumour-infiltrating immune cells (IC) in chemoradiotherapy-naïve primary EG tumours and paired lymph node metastases. Particular attention was given to the relationship with MSI status and prognosis.

Methods

PD-L1 expression in TC and IC was assessed by immunohistochemistry (IHC) on tissue microarrays with all primary tumours (n = 165) and paired lymph node metastases (n = 61) from a retrospective consecutive cohort of patients with chemoradiotherapy-naïve resected EG cancers. MSI was defined as loss of IHC expression of MLH1, MSH2, MSH2 or MSH6. Univariable and multivariable Cox regression analysis was used to calculate overall survival (OS).

Results

There was a significant correlation between TC and IC PD-L1 expression in primary tumours (p 

Conclusions

PD-L1 expression in TC does not differ significantly between primary tumours and lymph node metastases, PD-L1 expression in IC but not in TC is an independent favourable prognostic factor.

Clinical trial identification

Legal entity responsible for the study

Lund University

Funding

This study was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Mrs. Berta Kamprad Foundation, the Swedish Government Grant for Clinical Research (ALF), Lund University Faculty of Medicine, and the Lund University Hospital Research Grants.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.